Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/155346
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pasculli, Barbara | - |
dc.contributor.author | Barbano, Raffaela | - |
dc.contributor.author | Rendina, Michelina | - |
dc.contributor.author | Fontana, Andrea | - |
dc.contributor.author | Copetti, Massimiliano | - |
dc.contributor.author | Mazza, Tommaso | - |
dc.contributor.author | Valori, Vanna Maria | - |
dc.contributor.author | Morritti, Maria | - |
dc.contributor.author | Maiello, Evaristo | - |
dc.contributor.author | Graziano, Paolo | - |
dc.contributor.author | Murgo, Roberto | - |
dc.contributor.author | Fazio, Vito Michele | - |
dc.contributor.author | Esteller, Manel | - |
dc.contributor.author | Parrella, Paola | - |
dc.date.accessioned | 2020-04-15T09:23:47Z | - |
dc.date.available | 2020-04-15T09:23:47Z | - |
dc.date.issued | 2019-10-17 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | http://hdl.handle.net/2445/155346 | - |
dc.description.abstract | MicroRNA-210-3p is the most prominent hypoxia regulated microRNA, and it has been found significantly overexpressed in different human cancers. We performed the expression analysis of miR-210-3p in a retrospective cohort of breast cancer patients with a median follow-up of 76 months (n = 283). An association between higher levels of miR-210-3p and risk of disease progression (HR: 2.13, 95%CI: 1.33-3.39, P = 0.002) was found in the subgroup of patients treated with Epirubicin and Cyclophosphamide followed by Docetaxel. Moreover, a cut off value of 20.966 established by ROC curve analyses allowed to discriminate patients who developed distant metastases with an accuracy of 85% at 3- (AUC: 0.870, 95%CI: 0.690-1.000) and 83% at 5-years follow up (AUC: 0.832, 95%CI: 0.656-1.000). Whereas the accuracy in discriminating patients who died for the disease was of 79.6% at both 5- (AUC: 0.804, 95%CI: 0.517-1.000) and 10-years (AUC: 0.804. 95%CI: 0.517-1.000) follow-up. In silico analysis of miR-210-3p and Docetaxel targets provided evidence for a putative molecular cross-talk involving microtubule regulation, drug efflux metabolism and oxidative stress response. Overall, our data point to the miR-210-3p involvement in the response to therapeutic regimens including Docetaxel in sequential therapy with anthracyclines, suggesting it may represent a predictive biomarker in breast cancer patients. | - |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Nature Publishing Group | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1038/s41598-019-51581-3 | - |
dc.relation.ispartof | Scientific Reports, 2019, vol. 9, num. 1, p. 14913 | - |
dc.relation.uri | https://doi.org/10.1038/s41598-019-51581-3 | - |
dc.rights | cc-by (c) Pasculli, Barbara et al., 2019 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Ciències Fisiològiques) | - |
dc.subject.classification | Micro RNAs | - |
dc.subject.classification | Càncer de mama | - |
dc.subject.classification | Tractament adjuvant del càncer | - |
dc.subject.other | MicroRNAs | - |
dc.subject.other | Breast cancer | - |
dc.subject.other | Adjuvant treatment of cancer | - |
dc.title | Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 695393 | - |
dc.date.updated | 2020-04-15T09:23:48Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 31624308 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Fisiològiques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
695393.pdf | 2.09 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License